Illumina, Inc. Fiscal 2017 Form 10-K Summary
Business context and reporting period
Illumina is a global provider of sequencing- and array-based genetic analysis systems, consumables, services, and informatics tools. Its customers include research institutions, pharmaceutical and biotechnology companies, hospitals, clinical laboratories, consumer genomics companies, and agrigenomics organizations.
The filing covers the 52-week fiscal year ended December 31, 2017. The filing also provides unaudited fourth-quarter results for the 13 weeks ended December 31, 2017. Illumina reports Core Illumina and Consolidated VIEs, principally Helix after GRAIL was deconsolidated on February 28, 2017.
Key financial metrics
| Metric | FY 2017 | FY 2016 | Change |
|---|---|---|---|
| Revenue | $2.752 billion | $2.398 billion | 15% |
| Product revenue | $2.289 billion | $2.032 billion | 13% |
| Service and other revenue | $463 million | $366 million | 27% |
| Gross profit | $1.826 billion | $1.666 billion | 10% |
| Gross margin | 66.4% | 69.5% | Down 310 basis points |
| Income from operations | $606 million | $587 million | 3% |
| Operating margin | 22.0% | 24.5% | Down 250 basis points |
| Consolidated net income | $678 million | $428 million | 58% |
| Net income attributable to Illumina stockholders | $726 million | $463 million | 57% |
| Diluted EPS | $4.92 | $3.07 | 60% |
| Cash flow from operations | $875 million | $779 million | 12% |
| Capital expenditures | $310 million | $260 million | 19% |
Revenue growth was driven primarily by sequencing consumables, the NovaSeq platform, genotyping services, and service contracts. Consumables revenue increased 14% to $1.753 billion, instrument revenue increased 10% to $515 million, and service and other revenue increased 27% to $463 million.
At December 31, 2017, cash and cash equivalents were $1.225 billion and short-term investments were $920 million, for combined cash, cash equivalents, and short-term investments of $2.145 billion. Approximately $1.1 billion of this total was held by foreign subsidiaries. Total assets were $5.257 billion and total stockholders’ equity was $2.749 billion.
Debt included $633 million of 0% convertible notes due 2019 and $517 million of 0.5% convertible notes due 2021. Long-term debt reported on the balance sheet was $1.182 billion, including financing lease obligations. Neither convertible note series was convertible as of December 31, 2017.
Fourth-quarter 2017 results
| Metric | Q4 2017 | Q4 2016 |
|---|---|---|
| Revenue | $778 million | $619 million |
| Gross profit | $542 million | $419 million |
| Net income attributable to Illumina stockholders | $68 million | $124 million |
| Diluted EPS | $0.46 | $0.84 |
Fourth-quarter net income and diluted EPS declined despite higher revenue and gross profit. The filing does not provide a complete quarter-specific reconciliation of the decline, so the precise drivers are not clear from the summarized quarterly data.
Material changes versus the prior comparable period
- Revenue increased 15%, led by a larger sequencing installed base, consumables demand, NovaSeq shipments, genotyping services, and extended service contracts.
- Gross margin declined from 69.5% to 66.4%. Management cited an $18 million acquired-intangible impairment, a larger mix of lower-margin array services, inventory reserves related to product transitions, and lower initial instrument margins for NovaSeq.
- Research and development expense increased 8% to $546 million, while selling, general and administrative expense increased 15% to $674 million, reflecting higher headcount, facilities investment, product development, and Helix launch costs.
- GRAIL completed a financing and repurchased portions of Illumina’s holdings, reducing Illumina’s ownership from 52% to approximately 19% and eliminating consolidation. Illumina recorded a pretax gain of $453 million and received $278 million in proceeds.
- Cash flow from operations increased to $875 million from $779 million. Capital expenditures rose to $310 million from $260 million, primarily for facilities and equipment.
- Backlog increased to approximately $935 million from $650 million. Management expected approximately two-thirds of the 2017 year-end backlog to ship during fiscal 2018, although backlog may be delayed, modified, or cancelled.
Guidance, outlook, risks, contingencies, and unusual items
- Management stated that revenue was expected to continue increasing in 2018 and that research and development expense was expected to rise to support business growth and product development. The filing does not provide a specific 2018 revenue or EPS guidance range.
- Management expected future gross margins to depend on pricing, product and service mix, product transitions, inventory levels, royalties, manufacturing costs, and support obligations.
- The Tax Cuts and Jobs Act generated a provisional $150 million tax provision, primarily for the one-time transition tax on certain foreign earnings and remeasurement of U.S. deferred tax assets and liabilities. The estimate was subject to revision during the permitted measurement period.
- FY 2017 other income included the $453 million GRAIL deconsolidation gain, materially increasing pretax income and reported net income. This gain was nonrecurring and should be distinguished from operating performance.
- Key business risks include intense competition and rapid technological change; execution and customer adoption of new products such as NovaSeq; manufacturing capacity, quality, and single-source supplier risks; regulatory approval and reimbursement risks for clinical products; intellectual-property litigation; cybersecurity and data-privacy risks; foreign-exchange exposure; and dependence on research funding.
- Helix noncontrolling investors may have a right, after January 1, 2021 and subject to specified conditions, to require cash redemption of their interests. The reported redeemable noncontrolling interest was $220 million at year-end.
- Contractual obligations totaled $2.345 billion, including $1.159 billion of debt obligations, $752 million of operating leases, $294 million of build-to-suit leases, and $107 million of purchase obligations. The table excluded uncertain tax positions, the provisional transition tax, Helix redemption interests, and an $83 million venture-fund commitment because timing or amounts were uncertain.
- Illumina repurchased approximately $251 million of common stock in 2017, with $100 million remaining under the authorized program at year-end. The company has never paid cash dividends and did not expect to do so in the foreseeable future.
- The filing reports various ordinary-course legal claims, including intellectual-property, employment, and contractual matters. The company stated that it could not predict the ultimate outcome or reasonably estimate potential losses for matters without accrued liabilities.
Important facts for investors to verify
- Separate recurring operating earnings and cash generation from the $453 million GRAIL deconsolidation gain and the $150 million provisional tax-reform charge.
- Assess whether NovaSeq growth and consumables usage offset lower initial instrument margins and product-transition inventory reserves.
- Review the sustainability of the 66.4% gross margin and the effect of service mix, pricing, competition, and future product launches.
- Reconcile the sharp decline in fourth-quarter net income and EPS despite higher quarterly revenue and gross profit.
- Monitor conversion, refinancing, or cash-settlement risk related to the $1.150 billion principal amount of convertible notes due in 2019 and 2021.
- Evaluate the liquidity impact of capital expenditures, lease obligations, tax payments, share repurchases, Helix redemption provisions, and the $83 million venture-fund commitment.
- Track the regulatory, reimbursement, intellectual-property, supply-chain, cybersecurity, and clinical-market risks identified in Item 1A.
- Confirm the final accounting impact of U.S. Tax Reform and the effects of adopting new revenue-recognition and financial-instrument standards in 2018.